SCT installs cookies on its website to ensure its proper functioning and to improve your browsing experience. Learn more about SCT's privacy and cookie policy.
Please note that blocking certain cookies may prevent the site from functioning properly.
Essential cookies Essential cookies are necessary for the proper functioning of the website and are always set.
Functional cookies Functional cookies enhance your browsing experience.
Analytic cookies Statistical cookies collect (anonymous) data that can be used to optimize the website after analysis.
Cookies third parties Third-party cookies are placed by ancillary services (social media, Google, ...) used on this site.
Set your cookie preferences
Check the cookies you consent to.
They are necessary for purely technical reasons within the framework of the use of the website. These cookies are placed as soon as you access the site.
They ensure the optimal functioning of the website. You can refuse them or remove them using your browser settings, but your browsing experience will be significantly worse.
They allow us to analyze certain aspects, such as the number of visits to the website, to a particular page or to an advertising message. We only use this information to improve the content of our website or to launch a new campaign on a specific topic that generates a lot of interest.
This website uses features offered by third parties such as Google, YouTube, LinkedIn and Facebook. These features use third-party cookies that may be placed directly by these services when you visit this website. You can find more information about the different third-party cookies in the list of third-party cookies.
Set your cookie preferences
Check the cookies you consent to.
They are necessary for purely technical reasons within the framework of the use of the website. These cookies are placed as soon as you access the site.
They ensure the optimal functioning of the website. You can refuse them or remove them using your browser settings, but your browsing experience will be significantly worse.
They allow us to analyze certain aspects, such as the number of visits to the website, to a particular page or to an advertising message. We only use this information to improve the content of our website or to launch a new campaign on a specific topic that generates a lot of interest.
This website uses features offered by third parties such as Google, YouTube, LinkedIn and Facebook. These features use third-party cookies that may be placed directly by these services when you visit this website. You can find more information about the different third-party cookies in the list of third-party cookies.
Evotec, in partnership with the French Medicinal Chemistry Society SCT, is delighted to invite submissions for the “Prize for Excellence in Molecular Design” to be awarded for the second time to an exceptional young to mid-career scientific research talent from academia or industry. The successful candidate will be selected based on outstanding innovation and applied state-of-the-art molecular design skills that have contributed to a demonstrated advance to drug discovery boundaries. In particular, the assessment panel are keen to recognise “drug hunter” who have demonstrated excellence in drug design resulting in highly informative novel molecules significantly impacting the drug discovery project. Submissions preferably should be the subject of a published (or accepted) scientific article, will cover a “break-through” discovery or innovative technology/method, and may include the application of machine learning and artificial intelligence (AI).
Evotecis a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.
2023 Call for applications
Opening dates : 15 January 2023 – 15 March 2023 (at midnight)
Andreas Luttens, the winner of 2022, speaks about his experience in the video here.
Created in 2022 to award Excellence in Molecular Design.
Evotecand the SCTdeliver this prize annually to a young to mid-career scientific research talent from academia or industry.
The amount to be awarded is 3,000€ (three thousand euros).
Eligibility
The candidate:
will be a “drug hunter” (medicinal chemist, computational chemist, molecular architect, …) who has demonstrated adventurous and creative qualities to push the boundaries of the industry’s current thinking in drug design and data analysis.
should clearly demonstrate that they have significantly contributed to aspects relevant to excellence in molecular design within discovery research projects.
must have published a key article illustrating innovation in molecular design or should demonstrate that such publication is likely to be accepted.
should be an “early to mid-career researcher” and have a valid membership to the EFMC throughout their national EFMC-adhering organisation (NAO).
Nomination process
The candidacy report (5 pages max.) with a full description of the innovation, including the state-of-art-design, the context and the exceptional added value of the innovation and potential downstream value, any references/publications/patents, and a short CV of the candidate.
Sent as a single file to sct@sct-asso.fr and president@sct-asso.fr before the stated deadline, and named EVOTECPrize_NAME_FirstName.pdf.
Award Holder obligation
On top of the mandatory affiliation to one of the EFMC adhering societies for the year of application, the Award Holder should respect ethical criteria:
To promote SCT and EFMC among their network, and to be an EFMC-adhering society member at least one additional year after receiving their prize.
To promote the sponsor along his network, according to some pre-rules established with them.
To give a lecture at one of the SCT scientific events decided between SCT and Evotec.
Jury
The Jury is balanced between Evotec and SCT: 3 representatives from Evotec , 3 representatives from SCT (president, or his/her delegate + 2 other SCT representatives)
The laureate is selected by voting, based on the majority of the votes
Each member has one vote, except the SCT president who has 2 votes, but the 2 votes cannot be dissociated on 2 applicants.
Evotec Prize for Excelence in Molecular Design Recipients
2022: Andreas Luttens (University of Uppsala, SV).